Grant and Pitch Preparation for Re:Pair Genomics Inc.

Project scope
Categories
Biotechnology Grant writing Scientific researchSkills
analytical skills scientific literature research biotechnology genomics writing innovationRe:Pair Genomics Inc., a biotech startup, is seeking to secure funding to advance its innovative solutions in the genomics field. The project aims to identify potential non-dilutive funding sources, including grants and pitch competitions, that align with the company's mission and objectives. The team will conduct research to compile a list of suitable funding opportunities and analyze the requirements for each. Additionally, the project involves assisting in the preparation of application materials, ensuring they are tailored to meet the specific criteria of each funding source. This project provides an opportunity for learners to apply their research, writing, and analytical skills in a real-world context, while gaining insight into the biotech industry's funding landscape.
The deliverables for this project include a comprehensive report detailing potential funding sources, including grants and pitch competitions, with their respective deadlines and requirements. Additionally, the team will prepare draft application materials, such as grant proposals and pitch decks, tailored to at least two identified funding opportunities. This project will also involve scientific literature search and proposing potential projects to secure grant funding. These deliverables will equip Re:Pair Genomics Inc. with the necessary tools to pursue funding effectively.
Providing specialized, in-depth knowledge and general industry insights for a comprehensive understanding.
Sharing knowledge in specific technical skills, techniques, methodologies required for the project.
Supported causes
The global challenges this project addresses, aligning with the United Nations Sustainable Development Goals (SDGs). Learn more about all 17 SDGs here.
About the company
Re:Pair Genomics uses AI to design compact synthetic promoters, which are DNA sequences required for gene therapies to target specific cell types. Rather than spending six months to a year to design and validate promoters manually, our algorithm can produce designs ready for testing within a day.